Skip Navigation
ChemIDplus A TOXNET DATABASE LiteBrowseAdvanced

Substance Name: Dianhydrogalactitol [USAN:INN]
RN: 23261-20-3
UNII: 4S465RYF7M
InChIKey: AAFJXZWCNVJTMK-GUCUJZIJSA-N

Note

  • One of the cytotoxic dihalohexitols that may have alkylating antineoplastic activity. It causes bone marrow toxicity. The active form is thought to be the diepoxide.

Molecular Formula

  • C6-H10-O4

Molecular Weight

  • 146.141
 

Classification Codes

  • Alkylating Agents
  • Antineoplastic Agents
  • Antineoplastic Agents, Alkylating
  • Drug / Therapeutic Agent
  • Mutation Data
  • Noxae
* denotes mobile formatted website

Links to Resources


Search for this InChIKey on the Web

Names and Synonyms

Name of Substance

  • Dianhydrogalactitol
  • Dianhydrogalactitol [USAN:INN]

MeSH Heading

  • Dianhydrogalactitol

Synonyms

  • 1,2-5,6-Dianhydro-dulcitol
  • 1,2:5,6-Dianhydrogalactitol
  • 1,2:5,6-Diepoxydulcitol
  • DAD
  • DAG
  • Dianhydrodulcitol
  • Dianhydrogalactitol
  • Dulcitol diepoxide
  • Dulcitoldiepoxide
  • NSC 132313
  • UNII-4S465RYF7M

Systematic Name

  • Galactitol, 1,2:5,6-dianhydro-

Registry Numbers

CAS Registry Number

  • 23261-20-3

FDA UNII

  • 4S465RYF7M

Other Registry Numbers

  • 20978-29-4
  • 457899-38-6

System Generated Number

  • 0023261203

Structure Descriptors

InChI

1S/C6H10O4/c7-5(3-1-9-3)6(8)4-2-10-4/h3-8H,1-2H2/t3-,4+,5+,6-

InChIKey

AAFJXZWCNVJTMK-GUCUJZIJSA-N

Smiles

O[C@H]([C@H](O)[C@@H]1CO1)[C@H]2CO2

Toxicity

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
dog LDLo intravenous 16mg/kg (16mg/kg)   Cancer Treatment Reports. Vol. 60, Pg. 1585, 1976.
dog LDLo intravenous 16mg/kg (16mg/kg) GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"

BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
Cancer Treatment Reports. Vol. 60, Pg. 1585, 1976.
mouse LD50 intraperitoneal 15mg/kg (15mg/kg) GASTROINTESTINAL: OTHER CHANGES Cancer Chemotherapy Reports, Part 1. Vol. 56, Pg. 593, 1972.
mouse LD50 intravenous 21mg/kg (21mg/kg) GASTROINTESTINAL: OTHER CHANGES Cancer Chemotherapy Reports, Part 1. Vol. 56, Pg. 593, 1972.
mouse LD50 oral 7899ug/kg (7.899mg/kg)   National Cancer Institute Screening Program Data Summary, Developmental Therapeutics Program. Vol. JAN1986,
mouse LD50 subcutaneous 16500ug/kg (16.5mg/kg)   National Cancer Institute Screening Program Data Summary, Developmental Therapeutics Program. Vol. JAN1986,
rabbit LD50 intravenous 14gm/kg (14000mg/kg)   Cancer Chemotherapy Reports, Part 1. Vol. 56, Pg. 593, 1972.
rat LD50 intraperitoneal 11mg/kg (11mg/kg) GASTROINTESTINAL: OTHER CHANGES Cancer Chemotherapy Reports, Part 1. Vol. 56, Pg. 593, 1972.
rat LD50 intravenous 16mg/kg (16mg/kg)   Cancer Chemotherapy Reports, Part 1. Vol. 56, Pg. 593, 1972.
rat LD50 intravenous 16mg/kg (16mg/kg) GASTROINTESTINAL: OTHER CHANGES Cancer Chemotherapy Reports, Part 1. Vol. 56, Pg. 593, 1972.
rat LD50 oral 14mg/kg (14mg/kg) GASTROINTESTINAL: OTHER CHANGES Cancer Chemotherapy Reports, Part 1. Vol. 56, Pg. 593, 1972.

Physical Properties

Physical Property Value Units Temp (deg C) Source
log P (octanol-water) -1.29E+00 (none)   EXP
Water Solubility 9.97E+05 mg/L 25 EST
Vapor Pressure 1.01E-03 mm Hg 25 EST
Henry's Law Constant 1.94E-12 atm-m3/mole 25 EST
Atmospheric OH Rate Constant 2.18E-11 cm3/molecule-sec 25 EST

Physical property data is provided to ChemIDplus by SRC, Inc.